Clinical Trial Update: Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial of induction cetuximab (IM-C225) with gemcitabine and oxaliplatin in pancreatic cancer completed. Results were posted March 22, 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-03-22